
The management of prostate cancer is determined by the stage and grade* of the tumor and the serum concentration of prostate specific antigen (PSA) (see box page 62). Imaging is important in determining stage, in directing biopsies to confirm the presence of cancer and assess its grade, and in many current forms of management.
Does he have cancer?
Transrectal ultrasonography (TRUS), often in a urologists office, is the standard method of imaging possible prostate cancer. The examination is performed in the axial and sagittal planes with a high-frequency transducer, and the volume of the gland is estimated.4,5
Unfortunately, prostate cancer does not produce predictable sonographic changes. Between 60 percent and 70 percent of these cancers are hypoechoic, but some benign conditions also produce hypoechoic areas, and the positive predictive value (PPV) of this finding is no greater than 52 percent.4 As many as 40 percent of prostate cancers are isoechoic and thus invisible by TRUS.4 Moreover, only tumors in the peripheral zone can be imaged reliably.4 The deficiencies of the examination were summarized with the comment that specificity and sensitivity of conventional grey-scale TRUS for the detection of prostate cancer are disappointingly low.6 However, TRUS is critical to accurate tissue sampling during biopsy.7 Abnormal areas are sampled, and sextant biopsies are acquired to ensure examination of all areas of the gland.
Please refer to the October 2002 issue for the complete story. For information on article reprints, contact Martin St. Denis